ES2074879T3 - Uso de interleuquina-10 en inmunoterapia adoptiva de cancer. - Google Patents

Uso de interleuquina-10 en inmunoterapia adoptiva de cancer.

Info

Publication number
ES2074879T3
ES2074879T3 ES92905179T ES92905179T ES2074879T3 ES 2074879 T3 ES2074879 T3 ES 2074879T3 ES 92905179 T ES92905179 T ES 92905179T ES 92905179 T ES92905179 T ES 92905179T ES 2074879 T3 ES2074879 T3 ES 2074879T3
Authority
ES
Spain
Prior art keywords
interleukin
tils
cancer immunotherapy
adoptive cancer
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92905179T
Other languages
English (en)
Inventor
Di-Hwei Hsu
Kevin W Moore
Hergen Spits
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2074879T3 publication Critical patent/ES2074879T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE PREVE UN METODO PARA EMPLEAR INTERLEUKIN-10 EN LA INMUNOTERAPIA ADOPTIVA DEL CANCER. SE EXPANDE UNA POBLACION DE LINFOCITOS INFILTRADOS DE TUMOR (TILS) EN UN CULTIVO, EN PRESENCIA DE INTERLEUKIN-10 (IL-10). DESPUES DE LA ADMINISTRACION DE LOS TILS AL PACIENTE, SE ADMINISTRA UNA CANTIDAD EFECTIVA DE AMBOS IL-2 Y IL-10 PARA INCREMENTAR LA CITOTOXICIDAD DE LAS CELULAS TUMORALES DE LOS TILS Y PARA REDUCIR LOS EFECTOS COLATERALES CAUSADOS POR LA PRODUCCION DE CITOKINA INDUCIDA POR IL-2 EN LOS TILS Y OTRAS CELULAS DEL PACIENTE.
ES92905179T 1991-01-16 1992-01-15 Uso de interleuquina-10 en inmunoterapia adoptiva de cancer. Expired - Lifetime ES2074879T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64134291A 1991-01-16 1991-01-16

Publications (1)

Publication Number Publication Date
ES2074879T3 true ES2074879T3 (es) 1995-09-16

Family

ID=24571960

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92905179T Expired - Lifetime ES2074879T3 (es) 1991-01-16 1992-01-15 Uso de interleuquina-10 en inmunoterapia adoptiva de cancer.

Country Status (17)

Country Link
US (1) US5776451A (es)
EP (2) EP0567586B1 (es)
JP (1) JPH06505250A (es)
CN (1) CN1063308A (es)
AT (1) ATE124866T1 (es)
AU (1) AU1273992A (es)
DE (1) DE69203443T2 (es)
DK (1) DK0567586T3 (es)
ES (1) ES2074879T3 (es)
GR (1) GR3017597T3 (es)
IE (1) IE68836B1 (es)
IL (1) IL100667A0 (es)
MX (1) MX9200161A (es)
MY (1) MY108267A (es)
NZ (1) NZ241321A (es)
WO (1) WO1992012726A1 (es)
ZA (1) ZA92304B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW381026B (en) * 1993-01-13 2000-02-01 Schering Corp Method of extracorporally activating cytolytic activity of peripheral blood mononuclear cells and pharmaceutical composition comprising the activated peripheral blood mononuclear cells
JPH09508116A (ja) * 1994-01-20 1997-08-19 シェーリング コーポレイション 末梢血単核細胞溶解活性を刺激するためのｉｌ−１０の使用
US5770190A (en) * 1995-07-14 1998-06-23 Schering Corporation Method of treatment of acute leukemia with inteleukin-10
AU2062497A (en) * 1996-02-28 1997-09-16 University Of Medicine And Dentistry Of New Jersey Antisense interleukin 10 and methods of use
ES2322877T3 (es) 1996-08-30 2009-06-30 Human Genome Sciences, Inc. Interleucina 19.
AU6517900A (en) * 1999-08-03 2001-02-19 Smith & Nephew, Inc. Controlled release implantable devices
IL154925A0 (en) 2000-09-14 2003-10-31 Beth Israel Hospital Modulation of il-2 and il-15-mediated t cell responses
US7052686B2 (en) 2000-09-29 2006-05-30 Schering Corporation Pegylated interleukin-10
CA2515779A1 (en) 2003-02-14 2004-09-02 The Curators Of The University Of Missouri Contraceptive method and compositions related to proteasomal interference
US7294262B2 (en) * 2003-08-27 2007-11-13 Sta-Rite Industries, Llc Modular fluid treatment apparatus
EP2468293B1 (en) 2006-09-28 2014-10-22 Merck Sharp & Dohme Corp. Use of pegylated il-10 to prevent metastasis of a cancer or tumor to the lung
US20080089875A1 (en) * 2006-10-13 2008-04-17 Zheng Cui Methods and compositions for the treatment of cancer
JP2012510284A (ja) 2008-12-03 2012-05-10 プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダ ワクチンの開発のためのフェノール可溶性モジュリンの使用
PT2379115T (pt) 2008-12-17 2018-01-03 Merck Sharp & Dohme Produção de mono- e di-peg-il-10; e utilizações
US20100310591A1 (en) * 2009-01-28 2010-12-09 Robert Humphreys Ii-KEY HYBRID PEPTIDES THAT MODULATE THE IMMUNE RESPONSE TO INFLUENZA
BR112012012917A2 (pt) * 2009-11-30 2016-10-25 Biotest Ag anticorpo, ácido nucleico, vetor, célula hospedeira, método para a produção de um anticorpo ou um fragmento do mesmo, composição farmacêutica, método para tratar ou prevenir uma condição médica em um indivíduo, uso de um anticorpo ou fragmento do mesmo, e, métodos in vitro para neutralizar il-10 em uma amostra, in vitro para detectar a presença de il-10 em uma amostra e para diagnosticar lúpus eritematoso sistêmico (sle) em um indivíduo
WO2012123269A1 (en) 2011-03-11 2012-09-20 Proyecto De Biomedicina Cima, S.L. Immunogenic compositions and methods for their use
EP2505640A1 (en) 2011-03-29 2012-10-03 Neo Virnatech, S.L. Vaccine compositions for birnavirus-borne diseases
MX2015014438A (es) 2013-04-18 2016-05-18 Armo Biosciences Inc Metodos de uso de interleucina-10 para tratar enfermedades y trastornos.
EP3434277A1 (en) 2013-06-17 2019-01-30 Armo Biosciences, Inc. Method for assessing protein identity and stability
CA2920679A1 (en) 2013-08-30 2015-03-05 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
CA2928526A1 (en) 2013-11-01 2015-05-07 Spherium Biomed S.L. Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents
AU2014346537A1 (en) 2013-11-11 2016-05-19 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
JP2017507950A (ja) 2014-02-27 2017-03-23 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ レチノイン酸受容体関連オーファン受容体ガンマのアゴニストを使用する養子細胞療法及び関連治療方法
WO2015171558A2 (en) 2014-05-05 2015-11-12 Lycera Corporation BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
JP6728061B2 (ja) 2014-05-05 2020-07-22 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγアゴニストとして用いるテトラヒドロキノリンスルホンアミド及び関連化合物ならびに疾患の治療
CN106573072A (zh) 2014-06-02 2017-04-19 阿尔莫生物科技股份有限公司 降低血清胆固醇的方法
CA2963989A1 (en) 2014-10-14 2016-04-21 Armo Biosciences, Inc. Interleukin-15 compositions and uses thereof
MX2017004983A (es) 2014-10-22 2017-11-13 Armo Biosciences Inc Metodos para usar interleucina 10 para tratar enfermedades y trastornos.
US10618970B2 (en) 2015-02-03 2020-04-14 Armo Biosciences, Inc. Method of treating cancer with IL-10 and antibodies that induce ADCC
EP3292119A4 (en) 2015-05-05 2018-10-03 Lycera Corporation DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE
CN107847583A (zh) 2015-05-28 2018-03-27 阿尔莫生物科技股份有限公司 用于治疗癌症的聚乙二醇化白细胞介素‑10
JP6838004B2 (ja) 2015-06-11 2021-03-03 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγのアゴニストとしての使用及び疾患の治療のためのアリールジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物
MX2018002298A (es) 2015-08-25 2018-07-06 Armo Biosciences Inc Metodos de uso de interleucina 10 para el tratamiento de enfermedades y trastornos.
WO2018162450A1 (en) 2017-03-06 2018-09-13 Fundación Para La Investigación Médica Aplicada New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
WO2019143883A2 (en) * 2018-01-18 2019-07-25 Vedanta Biosciences, Inc. Compositions and methods for the treatment of cancer
CA3150859A1 (en) 2019-08-16 2021-02-25 Applied Molecular Transport Inc. Compositions, formulations, and interleukin production and purification
CN110669139A (zh) * 2019-09-18 2020-01-10 沣潮医药科技（上海）有限公司 二聚体免疫粘附素、药物组合物和用途
CN112625137B (zh) * 2019-10-08 2021-10-08 北京东方百泰生物科技股份有限公司 一种人白细胞介素10-Fc融合蛋白及其医药用途
CN114805538B (zh) * 2022-05-20 2023-06-09 广州智瓴生物医药有限公司 一种增强til功效的培养方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
JPH0751496B2 (ja) * 1986-04-02 1995-06-05 武田薬品工業株式会社 リポソ−ムの製造法
US4962091A (en) * 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
WO1990004633A1 (en) * 1988-10-21 1990-05-03 Brigham And Women's Hospital ACTIVATION AND GROWTH OF HUMAN TUMOR-INFILTRATING LYMPHOCYTES USING ANTIBODIES TO CD3 OR TcR
ATE110770T1 (de) * 1989-02-21 1994-09-15 Terumo Corp Proliferation von cd4-lymfocyten.
IL94878A (en) * 1989-06-28 2003-01-12 Schering Corp Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same

Also Published As

Publication number Publication date
WO1992012726A1 (en) 1992-08-06
MX9200161A (es) 1992-07-01
MY108267A (en) 1996-09-30
AU1273992A (en) 1992-08-27
IE68836B1 (en) 1996-07-10
GR3017597T3 (en) 1996-01-31
EP0567586B1 (en) 1995-07-12
ZA92304B (en) 1992-09-30
EP0567586A1 (en) 1993-11-03
JPH06505250A (ja) 1994-06-16
IL100667A0 (en) 1992-09-06
US5776451A (en) 1998-07-07
IE920113A1 (en) 1992-07-29
ATE124866T1 (de) 1995-07-15
EP0495639A1 (en) 1992-07-22
DE69203443D1 (de) 1995-08-17
NZ241321A (en) 1997-06-24
DE69203443T2 (de) 1995-12-07
CN1063308A (zh) 1992-08-05
DK0567586T3 (da) 1995-12-04

Similar Documents

Publication Publication Date Title
ES2074879T3 (es) Uso de interleuquina-10 en inmunoterapia adoptiva de cancer.
ES2032770T3 (es) Un procedimiento para producir farmacos de administracion nasal.
AR012614A1 (es) Una composicion farmaceutica para la fabricacion de un medicamento destinado para el tratamiento de una infeccion viral susceptible de tratamientocon interferon alfa, un metodo para la fabricacion de un medicamento, el uso de peg12000-ifn alfa para la fabricacion de un medicamento
ES2144426T3 (es) Terapia genica linfoquimica del cancer en combinacion con antigenos tumorales.
EP0857068A4 (en) IMMUNOTHERAPY OF CANCER AND INFECTIOUS DISEASES USING SENSITIZED ANTIGEN PRESENT CELLS WITH THERMAL SHOCK-ANTIGEN PROTEIN COMPLEXES
ES2040232T3 (es) Preparaciones medicinales para administracion oral conteniendo una sola dosis de 10 a 240 mg de dihidropiridina.
ES2530769T3 (es) Métodos para la activación de células T in vivo por células dendríticas pulsadas con antígeno
ES2112860T3 (es) Inmunoterapia adoptiva con interleukina-7.
DK421383D0 (da) Humant interleukin
DE68929208D1 (de) Anwendungen von Acemannan
ES2059537T3 (es) Metodo para purgar in vitro celulas tumorales residuales con la ayuda de celulas citotoxicas activadas por una linfocina.
IT1190041B (it) Procedimento di deprotezione di esteri ed eteri allilici,in particolare di derivati di carbapenem
IT1224594B (it) Impiego in terapeutica di derivati del 4h-benzo-4,5-cicloepta-1,2-bqti ofene
ES2137172T3 (es) Vacunas antitumorales que comprenden celulas transfectadas con il-6.
FR2427328A1 (fr) Ethers diphenyliques et medicament contenant ces substances
EP0248217A3 (en) Treatment of tumors with autologous lak cells, interleukin-2 and an ornithine decarboxylase inhibitor
DE69113802D1 (de) Anwendung von beta-alethin in zellkultur und therapie.
JPS57115180A (en) Preparation of human tyroid-stimulating hormone
YU4792A (sh) Postupak gajenja tumornih infiltirajućih limfocita
ES2059605T3 (es) Vacuna toxoide de la tosferina.
AR023643A1 (es) Formulaciones de vacuna de multiples antigenos
FR2358403A1 (fr) Nouveaux 2-imino-1,3-benzodithiolannes utiles notamment comme anti-inflammatoires
IT1209617B (it) Procedimento per la preparazione di alchilarileteri.
MUTO Immunological therapy of leukemia
ES2096081T3 (es) Utilizacion de interleuquina 10 para la preparacion de medicamentos con una actividad inhibidora de tumores.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 567586

Country of ref document: ES